Quantitative Systematic Strategies LLC Ascendis Pharma A/S Transaction History

Quantitative Systematic Strategies LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 04, 2020	SELL	$110.87 - $156.01 $247,240 - $347,902	-2,230 Closed	0 $0
Q1 2020 May 06, 2020	SELL	$97.01 - $145.11 $428,687 - $641,241	-4,419 Reduced 66.46%	2,230 $251,000
Q4 2019 Feb 11, 2020	BUY	$91.45 - $139.12 $608,051 - $925,008	6,649 New	6,649 $925,000
Q2 2019 Jul 25, 2019	SELL	$107.11 - $132.09 $235,427 - $290,333	-2,198 Closed	0 $0
Q1 2019 Apr 15, 2019	SELL	$62.15 - $129.99 $156,493 - $327,314	-2,518 Reduced 53.39%	2,198 $259,000
Q4 2018 Feb 12, 2019	SELL	$55.16 - $69.67 $26,752 - $33,789	-485 Reduced 9.33%	4,716 $295,000
Q3 2018 Nov 14, 2018	SELL	$63.77 - $76.28 $14,603 - $17,468	-229 Reduced 4.22%	5,201 $369,000
Q2 2018 Aug 07, 2018	BUY	$58.55 - $73.92 $317,926 - $401,385	5,430 New	5,430 $361,000
Q1 2018 May 04, 2018	SELL	$38.98 - $68.04 $261,711 - $456,820	-6,714 Closed	0 $0
Q4 2017 Feb 01, 2018	BUY	$31.98 - $40.38 $214,713 - $271,111	6,714	6,714 $269,000

228

56.6M

142K

259K

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.22B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

Get notified when there are updates to the investment portfolio of Quantitative Systematic Strategies LLC, based on Form 13F filings with the SEC.

Stay updated on Quantitative Systematic Strategies LLC with notifications on news.